FORMULATION AND IN-VITRO EVALUATION OF METFORMIN SUSTAINED RELEASE MATRIX TABLETS

Sustained released dosage form having an advantage over immediately release drug delivery system by continuous release of medicaments for a specific period in a prolonged manner. Diabetes mellitus (DM) is a common test endocrine issue that influences in excess of 100 million individuals ls around the world. Type II diabetes is characterized by peripheral insulin resistance and impaired insulin secretion. Metform in hydrochloride (Met) used in the treatment of type 2 diabetes, having a short half-life is a challenge for the researcher towards achieving sustained drug delivery systems. Met with higher dose shows high solubility and inherent compressibility. Towards the same, Met was formulated with different combinations of polymers such as chitosan, HPMCK 100 M and eudragit RL-100 by the wet granulation method. The formulated granules were subjected for a pre-compression study like bulk density, tapped density, compressibility index, Hausner’ sratio and angle of repose. The formulated tablets possess for post-compression studies. Drug-polymer interactions were investigated by FTIR studies. In-vitro drug release kinetics is carried out at pH 6.8. Formulation F7 has been found to be the best formulation and sustains the drug release 99.8% at 12 h. Obtained results reveal that when the concentration of eudragit RL-100 is more could be a good matrix for controlling the release rate of Met better than all other combinations. In-vitro release kinetic study carried out for all the formulations and followed the kinetics, say non-fickian and diffusion release.